Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

593 related articles for article (PubMed ID: 11259472)

  • 1. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of apoptosis and enhancement of chemosensitivity in human prostate cancer LNCaP cells using bispecific antisense oligonucleotide targeting Bcl-2 and Bcl-xL genes.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; So A; Zangemeister-Wittke U; Gleave ME
    BJU Int; 2006 Jun; 97(6):1300-8. PubMed ID: 16686729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence.
    Ziegler A; Luedke GH; Fabbro D; Altmann KH; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 1997 Jul; 89(14):1027-36. PubMed ID: 9230884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antisense-mediated downregulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy.
    Sharma H; Sen S; Lo Muzio L; Mariggiò A; Singh N
    Cancer Biol Ther; 2005 Jul; 4(7):720-7. PubMed ID: 15917659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cellular response to an antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic agents.
    Mercatante DR; Mohler JL; Kole R
    J Biol Chem; 2002 Dec; 277(51):49374-82. PubMed ID: 12381725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mcl-1 antisense therapy chemosensitizes human melanoma in a SCID mouse xenotransplantation model.
    Thallinger C; Wolschek MF; Wacheck V; Maierhofer H; Günsberg P; Polterauer P; Pehamberger H; Monia BP; Selzer E; Wolff K; Jansen B
    J Invest Dermatol; 2003 Jun; 120(6):1081-6. PubMed ID: 12787138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
    Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
    Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
    J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide.
    Strasberg Rieber M; Zangemeister-Wittke U; Rieber M
    Clin Cancer Res; 2001 May; 7(5):1446-51. PubMed ID: 11350916
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of Chinese herbal recipe Weichang'an in inducing apoptosis and related gene expression in human gastric cancer grafted onto nude mice].
    Zhao AG; Yang JK; You SF; Li T; Zhao HL; Gu Y; Tang LD; Qiu JX
    Zhong Xi Yi Jie He Xue Bao; 2007 May; 5(3):287-97. PubMed ID: 17498489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic delivery of siRNA specific to tumor mediated by atelocollagen: combined therapy using siRNA targeting Bcl-xL and cisplatin against prostate cancer.
    Mu P; Nagahara S; Makita N; Tarumi Y; Kadomatsu K; Takei Y
    Int J Cancer; 2009 Dec; 125(12):2978-90. PubMed ID: 19422046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antisense protein kinase A RIalpha acts synergistically with hydroxycamptothecin to inhibit growth and induce apoptosis in human cancer cells: molecular basis for combinatorial therapy.
    Cho YS; Cho-Chung YS
    Clin Cancer Res; 2003 Mar; 9(3):1171-8. PubMed ID: 12631623
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.
    Olie RA; Hall J; Natt F; Stahel RA; Zangemeister-Wittke U
    Biochim Biophys Acta; 2002 Jun; 1576(1-2):101-9. PubMed ID: 12031489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.